23 de diciembre de 2015 / 11:17 / hace 2 años

Kamada's rabies drug succeeds in trial

1 MIN. DE LECTURA

Dec 23 (Reuters) - Drugmaker Kamada Ltd said its rabies therapy had met the main goal in a large study, where it was found to be non-inferior to a reference product.

The drug, KamRab, is being developed as a post-exposure treatment for rabies and is already marketed in 10 countries worldwide, the company said on Wednesday.

Kamada plans to file for a marketing approval for the drug in the United States by mid-2016. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below